Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real World Outcome of Different Administrations of Recombinant human endostatin Combined With Chemotherapy in Driver Gene Mutation Negative Advanced Non Small Cell Lung Cancer patients.

Trial Profile

Real World Outcome of Different Administrations of Recombinant human endostatin Combined With Chemotherapy in Driver Gene Mutation Negative Advanced Non Small Cell Lung Cancer patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endostatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Oct 2018 New trial record
  • 26 Sep 2018 Primary endpoint has been met. (median overall survival) as per results presented at the 19th World Conference on Lung Cancer
  • 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top